SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Praxiss Investor Day and approaching FDA decisions for ulixacaltamide in essential tremor and relutrigine in developmental and epileptic encephalopathies are driving attention, alongside discussion of broader relutrigine trial data and launch preparations. Traders largely praise the commercial plans and potential markets, while some caution that approval, review timing and uptake remain uncertain.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

The FDA issued a Complete Response Letter for Summits ivonescimab application in EGFR-mutated lung cancer, citing the lack of a statistically significant overall-survival benefit despite positive progression-free-survival results. Traders are debating the setbacks impact: bears focus on the lost near-term approval and launch prospects, while bulls point to HARMONi-3 and the broader pipeline as remaining catalysts.

Helus Pharma, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is drawing attention ahead of expected Phase 3 APPROACH topline results for HLP003, its adjunctive major-depression treatment; traders view the readout as a high-stakes catalyst and debate whether the results will validate the programs promise. Optimism about the drugs potential is countered by concerns about clinical risk, dilution, and managements record.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus positive interim REGAIN data in recurrent glioblastoma is the main focus, with traders highlighting the early tumor responses and the companys view that expanded data may support a market submission. The reaction is strongly optimistic, though some emphasize that the cohort is small and want more detail on response durability and safety before drawing firm conclusions.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,112,050. The last known price of Bitcoin is 63,437.21016941 USD and is down -7.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $45,086,253,428.50 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff and volatile rebound dominate discussion, with traders divided between calling an oversold bounce or short squeeze and expecting further losses. The community attributes the pressure to possible liquidations, ETF selling, the Binance hack and macro headwinds, though these explanations remain debated.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

A nationwide FAA ground stop triggered by an air-traffic-control communications outage is driving attention, with widespread delays and cancellations raising concerns about Deltas operational costs and near-term results. Traders are split between viewing the disruption as a temporary setback now that the stop has been lifted and fearing lingering travel impacts; speculation about cyberattacks or deliberate action is unverified.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,563,191.01116 in circulation. The last known price of Stellar is 0.13466341 USD and is down -7.69 over the last 24 hours. It is currently trading on 849 active market(s) with $286,159,144.84 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

Discussion centers on Stellars planned DTCC tokenization integration and broader real-world-asset adoption, with traders debating whether institutional use will translate into demand for XLM. Many remain bearish over continued selling and weak price action despite the developments, while others view them as a long-term reason to accumulate.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is a major focus, with traders viewing the AI companys IPO filing as a potential valuation catalyst; a quarterly earnings beat and stronger full-year outlook also bolster the bullish case. Others question whether the stake can offset Zooms modest core-business growth and competitive pressures.

XPeng, Inc. is a global physical AI company, which engages in bringing artificial intelligence into the physical world to reshape future mobility and smart living. It developed a full-stack physical AI architecture spanning Turing AI chips, world foundation models, and integrated software and hardware applications. The firm's product portfolio includes smart EVs, robotaxis, and humanoid robots. The company's sales and services drives continuous technological innovation and fosters an open physical AI ecosystem, making life smarter, safer, and better for users worldwide. XPeng, Inc. was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPengs record October deliveries and upcoming Q3 results and guidance are driving attention, with traders weighing whether stronger sales and overseas growth can improve the outlook. Optimism about volume and the companys AI and robotics ambitions is tempered by concerns about margins, Chinas EV price war, and the stocks prolonged decline.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

VXX is drawing attention as traders react to a volatility uptick amid risk-off concerns and debate whether it signals a broader market pullback or a short-lived spike. Some are buying it as portfolio protection, while others expect volatility to fade and point to the products futures-roll decay.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$XBI biotech is the opposite of what everyone is talking about on tv

Not stable, not profitable , valued on expectation of future profits

What I can tell you is if you look at long term compare charts xbi always beats the $SPY by a lot! 

174 to to 70

Xbi has had many big draw downs in past , I been following this one for a decade plus

I will not post pre fda biotech stocks, I never post penny stocks 

What I will say is xbi is a really good aggressive etf for access to biotech and if u buy now and add a little if it goes lower, it will beat snp over next 5 years for sure imo , by a lot 

I can&#39;t believe xbi is down here , you can also look at $IBB $GDOC or $ARKG but I like xbi for it&#39;s equal weight access to the smaller innovative US biotech industry which has always done well. Also cheaper then the active options and much safer then individual biotech stocks 

This is the time especially on down days to buy xbi

KingSisyphus

lasse

Goldy

Tim Hortons

Mark K

StockTwits for iOS

iShares Biotechnology ETF

SPDR S&P Biotech ETF

ARK Investment Management LLC - ARK Genomic Revolution ETF

Goldman Sachs ETF Trust - Goldman Sachs Future Health Care Equity ETF

 biotech is the opposite of what everyone is talking about on tv

Not stable, not profitable , valued on expectation of future profits

What I can tell you is if you look at long term compare charts xbi always beats the 

 by a lot! 

174 to to 70

Xbi has had many big draw downs in past , I been following this one for a decade plus

I will not post pre fda biotech stocks, I never post penny stocks 

What I will say is xbi is a really good aggressive etf for access to biotech and if u buy now and add a little if it goes lower, it will beat snp over next 5 years for sure imo , by a lot 

I can't believe xbi is down here , you can also look at 

 but I like xbi for it's equal weight access to the smaller innovative US biotech industry which has always done well. Also cheaper then the active options and much safer then individual biotech stocks 

This is the time especially on down days to buy xbi